Sign In
Buy PASG
$4.47
-0.0200 (-0.445%)
At Close: Jul 31, 2026
Passage Bio to Participate in H.C. Wainwright 27th Annual Global Investment Conference
07:00am, Thursday, 28'th Aug 2025
PHILADELPHIA, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases,
Wall Street Analysts Believe Passage Bio (PASG) Could Rally 1415.15%: Here's is How to Trade
10:55am, Friday, 15'th Aug 2025
The mean of analysts' price targets for Passage Bio (PASG) points to a 1415.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among an
Passage Bio Reports Second Quarter 2025 Financial Results and Provides Recent Business Highlights
07:00am, Tuesday, 12'th Aug 2025
Completed dosing of FTD-GRN Cohort 2 in upliFT-D study Reported updated interim data showing that PBFT02 continued to demonstrate robust, durable elevation in CSF PGRN levels and improvement in plasma
Passage Bio Announces 1-for-20 Reverse Stock Split
07:00am, Thursday, 10'th Jul 2025
PHILADELPHIA, July 10, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (“Passage Bio” or the “Company”) (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of
Passage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program Update
07:00am, Monday, 23'rd Jun 2025
PBFT02 continued to demonstrate robust, durable elevation in CSF PGRN levels and improvement in plasma NfL, a disease progression biomarker, compared to natural history Dose 2, 50% lower than Dose 1,
Squarepoint Ops LLC Has $36,000 Stake in Passage Bio, Inc. (NASDAQ:PASG)
03:34am, Wednesday, 11'th Jun 2025
Squarepoint Ops LLC grew its holdings in shares of Passage Bio, Inc. (NASDAQ:PASG – Free Report) by 129.5% in the 4th quarter, according to the company in its most recent disclosure with the Sec
Passage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business Highlights
07:00am, Tuesday, 13'th May 2025
Treated first FTD-GRN patient with Dose 2 PBFT02 and enrolled second patient; several additional patients being evaluated for trial eligibility Announced presentation of process development data of a
Passage Bio (PASG) Upgraded to Buy: Here's What You Should Know
01:06pm, Friday, 07'th Mar 2025
Passage Bio (PASG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights
07:00am, Tuesday, 04'th Mar 2025
Interim data from Dose 1 PBFT02 demonstrated durable, elevated CSF PGRN and early evidence of reduction in plasma NfL levels, a disease progression biomarker, as compared to published natural history
Passage Bio to Participate in Upcoming Investor Conferences
07:00am, Wednesday, 26'th Feb 2025
PHILADELPHIA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases,
Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates
07:00am, Friday, 10'th Jan 2025
PBFT02 demonstrated durable, elevated CSF PGRN levels and early evidence of reduction in plasma NfL levels, a disease progression biomarker, compared to published natural history data
Passage Bio assumed with an Outperform at Wedbush
06:52am, Friday, 29'th Nov 2024
Wedbush assumed coverage of Passage Bio with an Outperform rating and price target of $4, up from $3. Market sentiment may be different from the days when an extensive gene therapy pipeline of four pr
Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference
07:00am, Wednesday, 06'th Nov 2024
PHILADELPHIA , Nov. 06, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases
Preclinical data demonstrated that an AAV1 vector achieved superior human progranulin levels in the CSF as compared to AAV5 and AAVhu68 (an AAV9 variant)
Passage Bio to Present at Chardan's 8th Annual Genetic Medicines Conference
07:00am, Monday, 23'rd Sep 2024
PHILADELPHIA, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases
